Vincenzo Cerullo

This inventor holds 11 USPTO granted patents and 11 published patent applications, plus 3 CIPO patents and 8 EPO patents. Top assignees: Valo Therapeutics Oy, Tilt Biotherapeutics Oy, Targovax Oy. Active years: 2016-2026.

USPTO Granted Patents = 11 (Patent Applications = 11)

% Patents Active = 81.8

CIPO Patents = 3 (Patent Applications = 10)

EPO Patents = 8 (Patent Applications = 17)

Average Co-Inventor Count = 4.1

ph-index = 3

Forward Citations = 27(Granted Patents)

Company Filing History:

Tilt Biotherapeutics Oy

Years Active: 2016-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12622935 - MODIFIED ONCOLYTIC ADENOVIRUSES (2026-05-12),

2. 12421502 - Enhanced adoptive cell therapy (2025-09-23),

3. 12337030 - Viral vector (2025-06-24),

4. 12031145 - Cancer therapy (2024-07-09),

5. 11730798 - Modified adenoviruses for cancer vaccines development (2023-08-22),

6. 10982194 - Non-genetic modification of enveloped viruses (2021-04-20),

7. 10799568 - Modified adenoviruses for cancer vaccines development (2020-10-13),

8. 10787645 - Enhanced adoptive cell therapy (2020-09-29),

9. 10647963 - Enhanced adoptive cell therapy (2020-05-12),

10. 9410129 - Recombinant serotype 5 (Ad5) adenoviral vectors (2016-08-09),

11. 9345787 - Adenoviral vectors and methods and uses related thereto (2016-05-24),

Title: Vincenzo Cerullo: Innovator in Cancer Therapy

Introduction

Vincenzo Cerullo is a prominent inventor based in Helsinki, Finland. He has made significant contributions to the field of cancer therapy, holding a total of 11 patents. His work focuses on innovative therapeutic methods that utilize oncolytic adenoviral vectors and adoptive cell therapy.

Latest Patents

Cerullo's latest patents include groundbreaking inventions in cancer treatment. One notable patent is for Enhanced Adoptive Cell Therapy, which discloses oncolytic adenoviral vectors used alone or in combination with therapeutic compositions for cancer treatment. This patent also covers the separate administration of adoptive cell therapeutic compositions and oncolytic adenoviral vectors, along with a pharmaceutical kit and composition utilizing these vectors. Another significant patent involves a novel viral vector with a modified viral capsid or envelope, which can be used in pharmaceutical compositions, immunogenic agents, or vaccines. This invention also details methods for treating cancer using the novel viral vector.

Career Highlights

Throughout his career, Vincenzo Cerullo has worked with notable companies in the biotechnology sector, including Valo Therapeutics and Tilt Biotherapeutics. His innovative approaches have positioned him as a key figure in the development of advanced cancer therapies.

Collaborations

Cerullo has collaborated with esteemed colleagues such as Akseli Hemminki and Markus Vähä-Koskela, further enhancing the impact of his research and inventions in the field of cancer treatment.

Conclusion

Vincenzo Cerullo's contributions to cancer therapy through his patents and collaborations highlight his role as a leading innovator in the field. His work continues to pave the way for new therapeutic strategies in the fight against cancer.